Xvivo Perfusion AB (XVIVO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Getinge AB

BONESUPPORT HOLDING AB

CellaVision AB

Surgical Science Sweden AB

Vitrolife AB

Biotage AB

MedCap AB

Elekta AB

Genovis AB

Bactiguard Holding AB

Xvivo Perfusion AB

Why is Xvivo Perfusion AB ?

With a fall in Net Sales of -15.24%, the company declared Very Negative results in Jun 25

The company has declared negative results in Mar 25 after 8 consecutive negative quarters
INTEREST(HY) At SEK 51.04 MM has Grown at 6,435.72%
PRE-TAX PROFIT(Q) At SEK -3.65 MM has Fallen at -111.18%
NET PROFIT(Q) At SEK 1.27 MM has Fallen at -95.34%

With ROE of 6.44%, it has a expensive valuation with a 2.42 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -62.53%, its profits have risen by 2.8% ; the PEG ratio of the company is 13.6

Underperformed the market in the last 1 year

Even though the market (OMX Stockholm 30) has generated returns of 8.01% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -62.53% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Xvivo Perfusion AB for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Xvivo Perfusion AB

-62.53%

16.34

57.90%

OMX Stockholm 30

8.01%

0.44

18.11%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

34.92%

EBIT Growth (5y)

58.04%

EBIT to Interest (avg)

3.87

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.15

Sales to Capital Employed (avg)

0.35

Tax Ratio

12.12%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

1.93%

ROE (avg)

3.50%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.42

EV to EBIT

47.37

EV to EBITDA

25.50

EV to Capital Employed

2.67

EV to Sales

5.77

PEG Ratio

13.58

Dividend Yield

ROCE (Latest)

5.64%

ROE (Latest)

6.44%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Sideways

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

OPERATING CASH FLOW(Y)

Highest at SEK 78.51 MM

-27What is not working for the Company

INTEREST(HY)

At SEK 51.04 MM has Grown at 6,435.72%

PRE-TAX PROFIT(Q)

At SEK -3.65 MM has Fallen at -111.18%

NET PROFIT(Q)

At SEK 1.27 MM has Fallen at -95.34%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.31%

NET SALES(Q)

Lowest at SEK 178.29 MM

OPERATING PROFIT(Q)

Lowest at SEK 22.75 MM

OPERATING PROFIT MARGIN(Q)

Lowest at 12.76 %

Here's what is working for Xvivo Perfusion AB

Operating Cash Flow

Highest at SEK 78.51 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (SEK MM)

Here's what is not working for Xvivo Perfusion AB

Interest

At SEK 51.04 MM has Grown at 6,435.72%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Pre-Tax Profit

At SEK -3.65 MM has Fallen at -111.18%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit

At SEK 1.27 MM has Fallen at -95.34%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (SEK MM)

Inventory Turnover Ratio

Lowest at 1.31% and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Net Sales

Lowest at SEK 178.29 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (SEK MM)

Operating Profit

Lowest at SEK 22.75 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (SEK MM)

Operating Profit Margin

Lowest at 12.76 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales